Filing Flows › Skinvisible (SKVI) › Q2 2026 › vs Q2 2025
Skinvisible (SKVI) Q2 2026 vs Q2 2025 (year over year)
Skinvisible's revenue rose $0 (0%) from $5K in Q2 2025 to $5K in Q2 2026.
Skinvisible, Q2 2026: revenue $5K (0% year over year), net loss $256K, operating cash flow $2K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $5K | $0 | 0% |
| Net loss | $256K | $274K | −$19K | -7% |
| Costs & expenses | $261K | $279K | −$19K | -7% |
| Operating costs | $118K | $141K | −$23K | -17% |
| Interest & other, net | $143K | $138K | $5K | +3% |
| Cost of revenue | $0 | $0 | $0 | — |
| SG&A | $113K | $136K | −$23K | -17% |
| Other operating costs | $5K | $5K | −$67 | -1% |
| Operating cash sources | $258K | $265K | −$8K | -3% |
| Depreciation & amortization | $5K | $5K | −$67 | -1% |
| Working capital & other | $253K | $260K | −$7K | -3% |
| Net loss absorbed | $256K | $274K | −$19K | -7% |
| Operating cash flow | $2K | −$9K | $11K | — |
Questions
How much did Skinvisible's revenue grow year over year in Q2 2026?
Skinvisible's revenue rose $0 (0%) from $5K in Q2 2025 to $5K in Q2 2026.